ClinicalTrials.gg
CompletedNCT04328766Updated Aug 16, 2021

Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

A Phase 1 interventional study of DWC202005, alone and DWP14012 + DWC202005 in Drug-drug Interaction, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Australia. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-16.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers

02

Conditions studied

  • Drug-drug Interaction
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy adults aged 19 to 50 years with between 18.5 kg/m2 and 30.0 kg/m2
  • Capable of understanding provided information and complying with protocol requirements
  • Provide written to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    DWP14012 Cohort A

    Drug: DWC202005, alone

  • Experimental
    DWP14012 Cohort B

    Drug: DWP14012 + DWC202005

  • Experimental
    DWP14012 Cohort C

    Drug: DWP14012 + DWC202005, after multiple doses of DWP14012

Interventions

  • DrugDWC202005, alone

    DWC202005, as a single dose

  • DrugDWP14012 + DWC202005

    Drug page: Fexuprazan

    DWP14012 and DWC202005, as a single dose

  • DrugDWP14012 + DWC202005, after multiple doses of DWP14012

    DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days

06

What researchers measure

Primary outcomes

  1. Area under the plasma drug concentration-time curve

    AUClast of DWC202005

    Time frame: upto 48 hours postdose

  2. Peak Plasma Concentration (Cmax)

    Cmax of DWC202005

    Time frame: upto 48 hours postdose

  3. Incidence of Treatment-Emergent Adverse Events

    Time frame: up to 19 days

07

Study locations

1 site
  • Nucleus Network (QPharm)
    Queensland, 78, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 31, 2020
StartActual
Sep 6, 2020
Primary completionActual
Nov 21, 2020
CompletionActual
Nov 21, 2020
Last update
Aug 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04328766
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Sep 6, 2020
Primary completion
Nov 21, 2020
Completion
Nov 21, 2020
Last update
Aug 16, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion